Printer Friendly

PAINEWEBBER ADDS BAUSCH & LOMB AND CONRAIL TO ITS FOCUS LIST

 PAINEWEBBER ADDS BAUSCH & LOMB AND CONRAIL TO ITS FOCUS LIST
 NEW YORK, Dec. 3 /PRNewswire/ -- PaineWebber Incorporated announced today that it has added two companies to its group of stocks known as the PaineWebber Focus List. They are Bausch & Lomb (NYSE: BOL) and Consolidated Rail Corp. (NYSE: CRR). The Focus List is a dynamic, carefully chosen list of select companies that the firm has rated buy or attractive.
 Since inception in 1982, the Focus List was up 611 percent(A) through the end of September 1991 on a total return basis. This performance compares favorably with that of the S&P Index at 371 percent.
 The Focus List uses a method of stock selection designed to maximize growth potential and minimize risk. The 30 stocks that comprise the Focus List are chosen by a committee of senior PaineWebber professionals whose selection criteria combine elements of fundamental, quantitative and technical analysis.
 After a stock is chosen, it is scrutinized daily and is removed from the list when one of two things happens: the PaineWebber analyst downgrades the stock, or the Focus List's proprietary Stop-Loss discipline indicates that the price threshold has been violated.
 Bausch & Lomb, headquartered in Rochester, N.Y., is the world's leading maker of contact lenses and related accessories. They also produce opthamolic drugs, dental plaque removal devices, sunglasses and consumer optical items. Company revenues were $1.4 billion in 1990, up from $1.2 billion in 1989.
 Consolidated Rail Corp. (Conrail), headquartered in Philadelphia, operates a network of 12,800 route miles in 13 Northeastern states. Conrail was formed from the rail assets of the bankrupt Penn Central Transportation Co. and five other railroads in 1976. Company revenues were $3.3 billion in 1990.
 Carolyn J. Cole, senior vice president and chairman of the Focus List committee, said about the selections, "We believe that both these companies are excellent additions to the Focus List. With 85 percent of its products ranked number one in the world, Bausch & Lomb's sales and earnings continue to show strong growth trends. Conrail has just successfully completed a major restructuring program, and is the best choice in the rail group."
 Tina Rizopolous, PaineWebber's medical technologies/health services analyst, said about Bausch & Lomb, "With extensive global presence, Bausch & Lomb would be a good defensive stock to invest in throughout the 1990s. Its established product lines, including many brand names such as Ray Ban and Interplak, provide the underpinnings for Bausch & Lomb's multinational business strategy."
 Anthony Hatch, PaineWebber's rail and trucking analyst, said about Conrail, "Conrail is the best way to play the railroad renaissance of the 1990s."
 To receive recent performance data or a complete list of stocks on the Focus List and additional information about those stocks, contact any investment executive at your nearest PaineWebber office.
 PaineWebber Incorporated is one of the nation's leading full-service securities firms with 270 offices and 4,500 investment executives worldwide.
 BOL Dec. 2, 1991, price: $53
 CRR Dec. 2, 1991, price: $73-7/8
 (A) -- Total return is a measure of capital appreciation plus dividends for the period from April 16, 1982, through June 30, 1991, excluding commissions. Adjustments for commissions would significantly reduce total return. Of course, past performance is no indicator of future results. Complete records of all transactions and details of methodology are available upon request.
 -0- 12/3/91
 /CONTACT: Beverly T. Spano of PaineWebber, 201-902-6775, or Jeffrey Z. Taufield of Kekst and Company, 212-593-2655, for PaineWebber/
 (BOL CRR) CO: Bausch & Lomb; Consolidated Rail Corp. ST: New York, Pennsylvania IN: SU:


TS-CK -- NY038 -- 8751 12/03/91 12:17 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:596
Previous Article:ALASKA AIRLINES, HORIZON AIR REPORT NOVEMBER TRAFFIC RESULTS
Next Article:GTE-LED CONSORTIUM CLOSES PURCHASE ON 40 PERCENT OF VENEZUELA'S NATIONAL TELEPHONE COMPANY; NAMES NEW CANTV PRESIDENT
Topics:


Related Articles
FOR THOSE DIAGNOSED WITH AN ASTIGMATISM, THERE'S GOOD NEWS FROM BAUSCH & LOMB
BAUSCH & LOMB SIGNS MULTIMILLION-DOLLAR SPONSORSHIP AGREEMENT WITH THE NBA
BAUSCH & LOMB OFFERS MONTHLY REPLACEMENT, CUSTOM-FIT CONTACT LENSES TO CORRECT ASTIGMATISM -- FREE!; GOOD NEWS FOR 35 TO 45 MILLION AMERICANS
MANY ATHLETES NEGLECT VISION CARE; MAY NOT BE AWARE THEY REQUIRE VISION CORRECTION; BAUSCH & LOMB SCREENS HUNDREDS OF ATHLETES
BAUSCH & LOMB TO TEST VISUAL SKILLS OF OLYMPIC ATHLETES
Bausch & Lomb Removed from Standard & Poor's Credit Watch; Commercial Paper Rating Remains Unchanged at A-2
Bausch & Lomb Settles 3-Year-Old Probe by 17 State Attorneys General Into an Obsolete Contact Lens Marketing Practice
MedPointe's Expanded Sales Force Will Promote OPTIVAR(R) to Eye-Care Physicians.
Crystalens HD(TM) Receives FDA Approval.
Bausch & Lomb Names Brian J. Harris as CFO and Corporate Vice President.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters